CARDIOMETABOLIC APPROACH TO THE MANAGEMENT OF METABOLICALLY ASSOCIATED FATTY LIVER DISEASE (MAFLD)
Keywords:
MAFLD, cardiometabolic approach, insulin resistance, fatty liver, dyslipidemia, metabolic syndromeAbstract
Background: Metabolically associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is now recognized as the hepatic manifestation of systemic metabolic dysfunction. The global increase in obesity, insulin resistance, and type 2 diabetes mellitus (T2DM) has positioned MAFLD as the leading cause of chronic liver disease worldwide. Cardiometabolic risk factors such as dyslipidemia, hypertension, and visceral adiposity are integral to its pathogenesis.
Objective: This study aimed to evaluate the cardiometabolic characteristics of patients with MAFLD and to assess the efficacy of an integrated cardiometabolic management strategy combining lifestyle modification, pharmacotherapy, and metabolic risk optimization.
Methods: A prospective study was conducted among 120 adult patients diagnosed with MAFLD between 2021 and 2024. Patients were divided into two groups: Group A (standard therapy) received conventional hepatoprotective treatment and dietary advice, whereas Group B (cardiometabolic approach) received individualized therapy targeting metabolic syndrome components alongside hepatoprotective care. Anthropometric, biochemical, and imaging parameters were evaluated at baseline and after 12 months of treatment.
Results: Baseline characteristics were comparable between groups. After 12 months, Group B demonstrated significantly greater reductions in body mass index (BMI), liver enzymes (ALT, AST), fasting glucose, and triglycerides. Mean hepatic fat content by ultrasound decreased by 38% in Group B compared to 17% in Group A (p < 0.001). Improvement in insulin resistance (HOMA-IR) correlated strongly with decreases in liver fat and serum triglycerides.
Conclusion: The cardiometabolic approach addressing systemic metabolic dysfunction significantly improves hepatic outcomes in MAFLD patients. Targeting insulin resistance, dyslipidemia, and visceral obesity alongside liver-directed therapy yields better metabolic and hepatic recovery than conventional treatment alone.
References
1.Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic-associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.
2.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2016;64(1):73–84.
3.Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–S64.
4.Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209.
5.Lonardo A, Ballestri S, Mantovani A, et al. Cardiometabolic risk in nonalcoholic fatty liver disease: mechanisms and therapeutic implications. Metabolism. 2020;111:154336.
6.Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease. Atherosclerosis. 2020;292:58–68.
7.Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis. Gastroenterology. 2012;142(4):711–725.
8.Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–1465.
9.Liu YL, Reeves HL, Burt AD, et al. TM6SF2 variant confers susceptibility to NAFLD. Nat Commun. 2014;5:4309.
10.Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–1231.
11.Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
12.Musso G, Cassader M, Rosina F, Gambino R. Impact of GLP-1 receptor agonists on liver fat and inflammation. Hepatology. 2012;55(2):466–475.
13.Bril F, Cusi K. Management of NAFLD in patients with type 2 diabetes: A cardiometabolic perspective. Diabetes Care. 2017;40(3):419–430.
14.Eslam M, George J. MAFLD: the redefinition of fatty liver disease. Nat Rev Gastroenterol Hepatol. 2020;17(8):453–454.
15.Tilg H, Moschen AR. Evolution of inflammation in NAFLD and NASH. Nat Rev Gastroenterol Hepatol. 2010;7(3):110–118.
16.Targher G, Byrne CD. Clinical significance of insulin resistance in NAFLD. Ann Hepatol. 2021;24:100339.
17.Mantovani A, Byrne CD, Bonora E, Targher G. MAFLD and risk of cardiovascular disease: an updated meta-analysis. Nat Rev Endocrinol. 2023;19(4):252–265.
18.European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Nonalcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
19.Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of NAFLD: Practice guidance. Hepatology. 2018;67(1):328–357.
20.Byrne CD, Patel J, Scorletti E. Nonalcoholic fatty liver disease: a cardiometabolic perspective. Clin Med (Lond). 2021;21(4):337–343.